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ABSTRACT 
 
Context: For the treatment of localised renal cell carcinoma (RCC) uncertainties remain over 
the perioperative and quality of life (QoL) outcomes for the many different surgical 
techniques and approaches of nephrectomy.  Controversy also remains on whether newer 
minimally invasive nephron-sparing interventions offer better QoL and perioperative 
outcomes, and whether adrenalectomy and lymphadenectomy should be performed 
simultaneously with nephrectomy.  These non-oncological outcomes are important because 
they may have a considerable impact on localised RCC treatment decision-making.  
Objective: To systematically review all the relevant published literature comparing 
perioperative and QoL outcomes of surgical management of localised RCC (T1-2N0M0).  
Evidence Acquisition: Relevant databases including MEDLINE, Embase and the Cochrane 
Library were searched up to January 2012. Randomised or quasi-randomised controlled 
trials (RCTs), prospective observational studies with controls, retrospective matched-pair 
studies, and comparative studies from well defined registries/databases were included.  The 
outcome measures were  QoL, analgesic requirement, length of hospital stay, time to 
normal activity level, surgical morbidity and complications, ischaemia time, renal function, 
blood loss, length of operation, need for blood transfusion and perioperative mortality.   
The Cochrane risk of bias (RoB) tool was used to assess RCTs and an extended version was 
used to assess non-randomised studies (NRS).  The quality of evidence was assessed using 
GRADE. Evidence Synthesis: 4580 abstracts and 380 full text articles were assessed.  29 
studies met the inclusion criteria (7 RCTs and 22 NRSs).  There were high risks of bias and 
low quality evidence for studies meeting the inclusion criteria.  Principal Findings:  There is 
good evidence indicating that partial nephrectomy results in better preservation of renal 
function and better QoL outcomes than radical nephrectomy regardless of technique or 
approach. Regarding radical nephrectomy, the laparoscopic approach has better 
perioperative outcomes than the open approach, and there is no evidence of a difference 
between the transperitoneal and retroperitoneal approaches.  Alternatives to standard 
laparoscopic radical nephrectomy such as hand-assisted, robotic assisted or single-port 
techniques appear to have similar perioperative outcomes. There is no good evidence to 
suggest that minimally invasive procedures such as cryotherapy or radiofrequency ablation 
(RFA) have superior perioperative or QoL outcomes to nephrectomy. Regarding concomitant 
lymphadenectomy during nephrectomy, there were low event rates for complications and 
no definitive difference was observed. There was no evidence to base statements about 
concomitant ipsilateral adrenalectomy during nephrectomy. Conclusions: Partial 
nephrectomy results in significantly better preservation of renal function over radical 
nephrectomy. For tumours where partial nephrectomy is not technically feasible, there is no 
evidence that alternative procedures or techniques are better than laparoscopic radical 
nephrectomy in terms of perioperative or QoL outcomes. In making treatment decisions, 
perioperative and QoL outcomes should be considered in conjunction with oncological 
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outcomes. Overall, there was a paucity of data regarding QoL outcomes, and when 
reported, both QoL and perioperative outcomes were inconsistently defined, measured or 
reported.  The current evidence base has major limitations due to studies of low 
methodological quality marked by high risks of bias.  
 
 
 
1. Introduction 
 
Nephron-sparing surgery (i.e. partial nephrectomy) and other minimally invasive 
interventions such as cryoablation, radiofrequency ablation (RFA) and high-intensity focused 
ultrasound (HIFU) are alternative options to radical nephrectomy in the management of 
localised (T1-T2N0M0) renal cell carcinoma (RCC) [1-7].  Although the decision to undertake 
these procedures are usually oncologically driven, there is a definite need for better 
understanding of non-oncological outcomes associated with these competing interventions, 
as they influence treatment decision-making. Presently, various guidelines exist in relation 
to the various interventions for localised RCC [1,5]. However, it is important to recognise 
that many current urology guidelines recommendations are not based on systematic 
reviews of the evidence [8]. Consequently, a systematic review of current evidence is 
urgently needed in order to establish whether the non-oncological outcomes of all these 
competing interventions are comparable. Such a review should be performed with 
methodological rigour in assessing risks of bias and quality of evidence in a standardised and 
transparent way to highlight potential weaknesses in the evidence base and highlight areas 
for future research.   
    
The objective of this systematic review was to compare the perioperative and quality of life 
(QoL) outcomes for all interventions relevant to the management of localised RCC.  The 
oncological outcomes of the review are co-published in a separate article [9].  There is also a 
full report published online [10] with extra methodological information and data for 
oncological and surgical (non-oncological) outcomes.  
 
 
2. Evidence Acquisition  
 
 
2.1 Search strategy 
 
The search was conducted in accordance with the principles outlined in the Cochrane 
Handbook of Systematic Reviews [11]. The databases searched were: MEDLINE (1950-
October 2010) and Embase (1980–October, 2010), Cochrane Library-all sections (Issue 4, 
2010), Web of Science – with Conference Proceedings (1970-October 2010), and ASCO 
(American Society of Clinical Oncology) meeting abstracts (up to October 2010). The 
searches were not limited by language. Auto-alerts in MEDLINE and EMBASE were also run 
during the course of the review. Reference lists of relevant articles were also checked [10]. 
All abstracts and full-text articles were screened independently by two reviewers. 
Disagreement was resolved by discussion, and where no agreement was reached, a third 
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independent party acted as an arbiter. In addition, an updated search was carried out to 
cover the period from October 2010 to January 2012. 
 
2.2 Types of study design included  
 
All relevant randomised or quasi-randomised controlled trials (RCTs) were included.   Due to 
the small number of RCTs, we also included non-randomised studies (NRS).  Prospective 
observational studies with controls, retrospective matched-pair studies, and comparative 
studies from well-defined registries/databases were also included.  Studies with no 
comparator group (for example, case series); non-matched retrospective studies and chart 
reviews were excluded because of their higher risks of bias.  
 
 
2.3. Types of participants 
 
The study population was patients diagnosed with localised RCC based on CT scan or MRI, 
defined as clinical stage T1a-T2, N0, M0.  Studies that reported pathological T3 cases were 
included so long as the clinical staging was T1-2 N0 M0.  
 
 
2.4 Types of intervention 
 
The following interventions were compared: 
 
 Radical nephrectomy 
 Partial nephrectomy   
 Laparoscopic surgery for radical or partial nephrectomy  
 Hand-assisted laparoscopic surgery for radical or partial nephrectomy 
 Robotic surgery for radical or partial nephrectomy 
 Laparoscopic-assisted radiofrequency ablation (RFA) 
 Laparoscopic-assisted cryoablation 
 Laparoscopic-assisted high intensity focused ultrasound (HIFU) 
 
A valid comparator was no intervention (i.e. active surveillance) or any of the specified 
interventions [10]. Ablative procedures performed percutaneously (such as percutaneous 
radiofrequency ablation) were excluded as they are not traditionally regarded as surgical 
treatment options. 
 
The following interventions were also included in the review as additional procedures 
performed concurrently with either radical or partial nephrectomy: 
 
 Complete regional (extended) lymphadenectomy 
 Partial regional (limited) lymphadenectomy 
 Adrenalectomy 
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2.5. Types of outcome measures 
 
The outcome measures of effectiveness are outlined below.  
 
 Quality of Life Outcomes  
 
General health status measures e.g. Short Form 36 [12]  
   
 
Perioperative Outcomes  
 
 Surgical site infection 
 Pneumonia 
 Urinary tract infection 
 Deep venous thrombosis 
 Haemorrhage requiring transfusion 
 Renal failure or decline in renal function 
 Ischaemia time  
 Overall morbidity 
 Estimated blood loss 
 Length of operation 
 Need for blood transfusion 
 Analgesic requirement 
 Length of hospital stay 
 Time to normal activity level 
 Operative 30-day mortality rate 
 Operative 90-day mortality rate 
 
 
Other Perioperative and Quality of Life Outcomes  
Non pre-specified outcomes judged important when performing the review. 
 
 
2.6 Assessment of risks of bias 
 
The risk of bias (RoB) in the included studies was assessed using the Cochrane Risk of Bias 
Assessment tool for RCTs [11]. A modified version of the RoB assessment tool was used in 
assessing NRS with the addition of further items (domains) to assess risk of bias through 
confounders [13].   
 
A list of the four most important potential confounders (prognostic factors) for 
perioperative and quality of life outcomes identified a priori in consultation with content 
experts (drawn from the British Association of Urological Surgeons Section of Oncology and 
European Association of Urology Renal Cancer Guideline Panel) is given below: 
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 Performance status 
 Age 
 Co-morbidity 
 Ethnicity 
 
The assessment of the pre-specified confounders is outlined in detail elsewhere [10]. 
 
 
2.6.1 Assessment of the quality of evidence 
 
Out of the seven outcomes chosen for GRADE quality assessment in consultation with 
clinical content experts, two were oncological outcomes and five were non-oncological 
outcomes [10].  The five surgical and QoL outcomes are reported in this review and are 
listed as follows:  
 
Critical: 
 Condition-specific QoL 
 Overall morbidity rates  
 Time to normal activity level  
 
Important: 
 Analgesic requirement 
 Need for blood transfusion  
 
 
2.7 Data analysis 
 
Outcomes were abstracted from included studies in the form of total numbers and 
proportions for dichotomous outcomes and total numbers, means and standard deviations 
(SD) for continuous outcomes. By default, dichotomous outcomes were analysed using fixed 
effect models to estimate relative risk (risk ratios) with 95% confidence intervals (CI). 
Continuous outcomes were analysed using a fixed effects model to estimate the (weighted) 
mean difference and 95% CI.  When using relative risks, if 95% CI in individual studies do not 
cross the line of no effect (i.e. one) then the result can be regarded as statistically significant 
at the p = 0.05 level.  When using mean difference, if 95% CI in individual studies do not 
cross the line of no effect (i.e. zero) then the result can be regarded as statistically 
significant at the p = 0.05 level.  A quantitative synthesis (meta-analysis) was performed for 
RCT data only where appropriate.  The results of the limited number of meta-analyses 
undertaken for RCT data are mentioned in the text. Heterogeneity of data and high risks of 
bias arising from selection bias made meta-analysis inappropriate for NRS.   The Forest plots 
show results of individual studies comparing the same interventions and reporting the same 
outcomes but pooled estimates are not provided for the methodological reasons outlined 
above. Where meta-analysis was not feasible, then a narrative synthesis is provided.  
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Heterogeneity between studies was assessed using the χ² test for heterogeneity and the I² 
statistic [14].    Analysis was performed in the Cochrane RevMan software (version five).   
 
Separate or subgroup analyses were planned but data were not sufficient to address any of 
these meaningfully [10].  
 
 
3.  Evidence synthesis 
 
3.1. Risk of Bias and Quality assessment of the included studies 
 
The study selection process is outlined in the PRISMA Diagram (Fig 1).  There were 39 
studies that met the inclusion criteria, and 28 (72%) of which reported surgical outcomes, of 
which only 7 (25%) were RCTs. The Cochrane RoB assessment can be viewed in Appendix 1. 
The additional non-randomised risk of bias assessment adjustment scores (outlined above) 
are displayed in Table 1 which reports baseline characteristics (all study designs) and 
adjustment scores (NRSs only).   
 
 
3.2 Comparisons of interventions results  
 
3.2.1 Is surgery better than no surgery (i.e. active surveillance)?  
There were no studies that assessed this comparison in terms of perioperative and QoL 
outcomes.  
 
3.2.2 For radical nephrectomy, is the laparoscopic approach better than the open 
approach?  
Data were obtained from one RCT (Peng, 2006) [15] and two NRS (Gratzke, 2007 and Hemal, 
2007) [16,17].  Mean length of hospital stay was significantly shorter in the laparoscopic 
radical nephrectomy group in all three studies [16],  (Fig 2).  There was no evidence of a 
difference in number of patients receiving a blood transfusion (Fig 3).  Analgesic 
requirement was significantly lower in the laparoscopic radical nephrectomy arm in Hemal’s 
study (Fig 4), and lower in the laparoscopic arm in Peng’s study [15] but statistical 
significance is not estimable because no measure of spread is given [10].  Mean difference in 
convalescence time (weeks) was significantly shorter in the laparoscopic arm compared to 
the open arm in Hemal’s study [17] (Fig 5).  Mean difference in blood loss was significantly 
less in the laparoscopic arm in all three studies [15-17] (Fig 6).  Surgical complications were 
marked by low event rates and very wide confidence intervals. There was no evidence of a 
difference in the rates of surgical site infection [16,17], pneumonia [16], haemorrhage [16], 
and  postoperative mortality  [10].  Mean difference in duration of operation (minutes) was 
significantly shorter in the open arm compared with the laparoscopic arm in Gratzke’s [16] 
and Hemal’s [17] studies, but there was no evidence of a difference in Peng’s RCT [15] (Fig 
7).  
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Post-operative QoL scores were similar between groups in Gratzke’s study [16] (Table 2). 
However, patients who had postoperative complications (regardless of the type of surgery) 
tended to have worse QoL scores compared with patients without complications [16].  The 
trend reached statistical significance in the general health domain (p<0.05).   
 
3.2.3. For laparoscopic radical nephrectomy, are alternative approaches better 
than the standard 3-port transperitoneal approach?  
Two randomised studies (Desai 2005a; Nambirajan 2004) [18,19] and one quasi-randomised 
study (Nadler 2006) [20] compared retroperitoneal and transperitoneal laparoscopic radical 
nephrectomy.  All three trials provided information on operation time and length of hospital 
stay. Meta-analysis on operation time found a small difference favouring the retroperitoneal 
approach (Fig 7), although there was significant statistical heterogeneity (I2 = 89%).  The 
reason for heterogeneity is unclear. There was no evidence of a difference in length of 
hospital stay between the two approaches (Fig. 2).  It should be noted that the sample size is 
very small (11 in each arm) in Nadler’s study [20].  Meta-analysis of data from the three 
trials on intra-operative blood loss found no significant difference between the two 
approaches (Fig 6).  Other postoperative adverse events appear uncommon in the included 
studies [10] and  there were no clear differences for these outcomes. Analgesic requirement 
did not differ between the groups (Fig. 4) whilst the results for time to normal activity 
revealed inconsistent findings (Fig. 5), (Fig. 8).  
 
One quasi-RCT (Nadler, 2006) [20] and one NRS (Gabr 2009) [21] compared hand-assisted 
with standard (i.e. transperitoneal) laparoscopic radical nephrectomy.  Length of hospital 
stay and time to non-strenuous activities (mean days) were significantly shorter for standard 
laparoscopic radical nephrectomy [20] [[21] (Figs 2 and 9), however, the sample size was 
small (11 patients in each arm).  There was no evidence of a difference in other 
perioperative, recovery and mental health outcomes (Figs 4, 6, and 8)[20] [10,21], .   
 
One quasi-randomised study compared hand-assisted laparoscopic versus standard 
retroperitoneal laparoscopic radical nephrectomy (Nadler) [20].  Duration of operation was 
significantly shorter in the hand-assisted compared to the retroperitoneal approach (Fig 7), 
but the sample size was small (11 in each arm).  There was no evidence of a difference in 
other perioperative outcomes (Figs 2, 4, 6 and 8) 
 
One prospective cohort study compared robotic versus laparoscopic radical nephrectomy 
[22].  There was no evidence of a difference in perioperative outcomes (Figs 2, 3 and 4)   
 
Two observational studies [23,24] compared ‘portless’ (i.e. single port) and 3-port 
laparoscopic radical nephrectomy.  One study [23] did not report adequate data  to allow 
statistical comparison.  There was no evidence of a difference in perioperative outcomes 
(Figs 2, 3, 6 and 7) [23,24].   
 
3.2.4. Is partial nephrectomy better than radical nephrectomy? 
 
i. Open partial nephrectomy vs. open radical nephrectomy  
Two RCTs (D’Armiento, 1997; Van Poppel, 2007) [25,26], a prospective cohort study 
(Poulakis, 2003) [27], a database review (Butler, 1995) [28] and three matched pair studies 
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(Shekarriz, 2002; Lee, 2007 and Gratzke, 2009) [16,29,30] were identified that compared 
various aspects of QoL and safety of open radical nephrectomy with open partial 
nephrectomy.  In these studies tumour size inclusion criteria can be generally classified as 
small renal tumours.  In Van Poppel’s study [26], tumour size inclusion criteria was less than 
or equal to 5cm.  Gratzke’s study [16] does not give any information on tumour size but 
tumour stages T1-T2 were included.  Shekarriz [30] limited inclusion criteria to less than 
7cm, but did not stratify analysis by <4cm and 4-7cm: the reported mean tumour sizes were 
close to 4cm and the standard deviations imply that a proportion of the participants had 
tumours in the 4-7cm range in both the radical and partial nephrectomy groups (4.2 cm 
(1.9) vs. 3.8 cm (2.46)).  Poulakis [27] did not exclude patients with regard to tumour size, 
but did conduct subgroup analyses to reflect the <4cm and 4-7cm controversy.  
 
There was no evidence of a difference in length of hospital stay [16,28,30] (Fig 2), number of 
patients requiring a blood transfusion [16,28,30] (Fig 3), or mean blood loss [16,30] (Fig 6).  
The RCT by Van Poppel et al [26] showed no evidence of a difference in severe haemorrhage 
(i.e. blood loss over 1L): RR 2.99 (95%CI 0.82, 10.92).   
In general, complication rates were inconsistently reported in the NRSs, and event rates 
were low and do not favour one intervention over the other [10].  Shekarriz [30] found the 
mean duration of operation significantly longer for the open partial group but Gratzke [16] 
found no evidence of a difference  (Fig 7).  
 
Two studies reported QoL post-surgery for RCC. In Poulakis’ prospective study [27] (N = 51), 
patients who underwent partial nephrectomy reported better scores, improving with time, 
in many aspects of QoL as measured by SF36 and EORTC QLQ-30. Those who underwent 
radical nephrectomy reported a higher degree of fear associated with living with only one 
kidney, but also less fear of recurrence (Poulakis 2003) [27] (Table 2). Regardless of 
intervention, patients with tumours < 4cm in size and a normal contralateral kidney showed 
the highest QoL performance with return to their normal QoL scores after treatment 
(Poulakis, 2003) [27].  72% of Gratzke et al’s (2009) [16] study group responded to the SF36 
QoL questionnaire (N = 34 for open partial nephrectomy and 27 for open radical 
nephrectomy).  The mean mental and physical component scores were similar between the 
groups (mental component: partial 44.5 vs. radical 48.3; physical component: partial 47.2 vs. 
radical 48) (Table 2) and the results were within one standard deviation of the age-matched 
norm, although patients who had higher complications rates had lower QoL scores.   
 
Mean (range) warm ischemia time (WIT) for the partial nephrectomy arm in Gratzke’s study  
[16] was 18 (9-39) minutes (Table 2). None of the other studies in this comparison reported 
WIT.  Three studies consistently reported worse renal function after radical nephrectomy 
compared to partial nephrectomy [26,28,29].  The RCT by Van Poppel [26] reported 
significantly lower median creatinine level at follow up in the partial nephrectomy group 
than in the radical nephrectomy group (1.29 mg/dl vs. 1.50 mg/dl respectively; p<0.0001) 
(Table 2). Butler [28] found a significantly higher mean postoperative serum creatinine level 
compared with preoperative levels after radical nephrectomy (preoperative: 1.1 (0.3) mg/dL 
vs. postoperative: 1.5 (0.4) mg/dL; preoperative: 97 (26) µmol/L vs. postoperative: 133 (35) 
µmol/L (p = >0.001)) but there was no evidence of a difference in the preoperative and 
postoperative serum creatinine levels after partial nephrectomy (preoperative: 1.3 (0.4) 
mg/dL vs. postoperative: 1.3 (0.6)  mg/dL,  preoperative: 115 (35) µmol/L vs. postoperative: 
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115 (53) µmol/L (p = not significant)) (Table 2). A significantly greater proportion of patients 
in the radical nephrectomy group had impaired postoperative renal function (defined as 
serum creatinine > 1.6mg/dL) after controlling for diabetes, hypertension and age (data not 
shown) in the study by Lee [29].   
 
ii. Laparoscopic partial nephrectomy vs. laparoscopic radical nephrectomy 
A database review (Simmons 2009) [31] compared 35 laparoscopic partial nephrectomy and 
75 laparoscopic radical nephrectomy cases in tumours larger than 4cm over a five-year 
period (2001-2005). Mean (SD) WIT for the laparoscopic partial nephrectomy group was 37 
(11) minutes (Table 2). There was a significantly greater decrease in the estimated GFR 
(decrease of 13 vs. 24 ml/min, p = 0.03) in the laparoscopic radical nephrectomy group and 
there was a significantly greater proportion of patients with a two-stage increase in the 
Chronic Kidney disease (CKD) stage in the laparoscopic radical nephrectomy group (0 vs. 
12%, p = <0.001) (Table 2).   
 
One database review (Dash, 2006) [32] was identified that compared partial and radical 
nephrectomy (by open or laparoscopic approach) in tumours 4-7cm in size.  The increase in 
post-operative mean creatinine was significantly smaller in the partial nephrectomy group 
(difference between means at three months:  0.23 mg/dl; 95% CI 0.11-0.34, p < 0.01, and at 
6-12 months: 0.21 mg/dl, 95% CI 0.09-0.34, p < 0.01) (Table 2).  
 
 
3.2.5 Which is the best approach to perform partial nephrectomy? 
 
i. Laparoscopic partial nephrectomy (LPN) vs. open partial nephrectomy (OPN) 
Two database reviews (Gill 2007, Lane 2010) [33,34] and two matched-pair analyses 
(Marzalek 2009, Gong 2008) [35,36] compared laparoscopic versus open techniques of 
partial nephrectomy.  Gong et al [35] found that length of hospital stay was significantly 
shorter in the LPN group (Fig 2).  Gill et al [33] reported the same direction of effect but did 
not report a measure of spread so statistical significance could not be tested (Fig 2).  There 
were significantly more blood transfusion events in the LPN group in Gill’s study [33], but 
there was no evidence of a difference for Gong‘s [35] and Marszalek’s  [36] studies  (Fig 3).  
Gong [35] reported significantly less mean blood loss in the LPN group (Fig 6).  Gill et al [33] 
also reported less mean blood loss in the LPN group but did not report a measure of spread 
so statistical significance could not be tested (Fig 6). Postoperative pneumonia and UTI 
event rates were very low and showed no consistent findings.  There were significantly 
more postoperative haemorrhages in the LPN group in Gill’s  study [33] but no difference in 
Gong‘s [35] and Marszalek’s  [36] studies [10]. There was no evidence of any differences 
between the groups in postoperative mortality [33,35], deep vein thrombosis (DVT) [35], or 
pulmonary embolism events [10,35,36]. Operative duration was significantly longer in the 
LPN group in Gong’s study [35] (Fig 7). Gill [33] reported mean operative times of 201 vs. 
266 minutes in the LPN versus OPN groups but did not report a measure of spread so 
statistical significance could not be tested. 
 
WIT was significantly longer in the LPN arm compared with the OPN arm in Gill’s study 
(mean [range] WIT 30.7  [4, 68] minutes for LPN vs 20.1 [4, 52] minutes for OPN; relative risk 
1.69, 95%CI 1.62, 1.77; p = <0.0001) whilst controlling for age, clinical tumour size, 
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contralateral kidney function and bilateral disease status (Table 2).  Similarly, mean (SD) WIT 
was significantly longer in the LPN group compared with the OPN group in Gong’s study 
(32.8 (10.6) vs. 20.5 (6.6) minutes).  In Marszalek’s study, median [IQR] warm ischemia time 
in the LPN group was 23 [19,27] minutes, compared with median [IQR] cold ischemia time in 
the OPN group of 31 [24,45] minutes (p = <0.001) (Table 2). However, the authors did not 
state the reason for comparing WIT against cold ischaemia time.  
 
Decline in glomerular filtration rate (GFR) was significantly greater in the LPN group in the 
immediate postoperative period in Marszalek’s study [36] (8.8% vs. 0.8% decline, p = 
<0.001), but the difference was not significant after a mean further follow-up of 3.6 years 
(10.9% vs. 10.6%, p = 0.8) (Table 2).  There was no evidence of a difference in postoperative 
change in creatinine between the LPN and OPN groups in Gong’s study [35] (0.03 vs. 0.21 
mg/dL, p = 0.27) and the lowest serum creatinine within 90 days of surgery showed no 
evidence of a difference in Gill’s study [33] (1.18 vs. 1.42 mg/dL) (Table 2). It is important to 
note that the evidence base for this comparison remains poor, with all studies suffering 
from the high risks of bias inherent in most NRS.   
 
ii. Robotic partial nephrectomy vs. laparoscopic partial nephrectomy  
Aron (2008) [37] compared robotic laparoscopic partial nephrectomy versus standard 
laparoscopic partial nephrectomy in a matched-pair analysis. There was no evidence of a 
difference in perioperative outcomes [10] nor in the estimated GFR between both groups at 
baseline or at three months postoperatively (Table 2). There was no evidence of a difference 
in mean (SD) WIT in the robotic laparoscopic partial nephrectomy arm (23 (6.6) minutes) 
compared with the laparoscopic partial nephrectomy arm (22 (10.8) minutes, p = 0.89) 
(Table 2). However, there were very few patients in the study (n=24) and patients were not 
randomly assigned.  
 
iii. Radiofrequency-assisted robotic clampless partial nephrectomy (RFRLPN) vs. 
laparoscopic partial nephrectomy  
Wu (2010) [38] reported a database review comparing patients who underwent standard 
laparoscopic partial nephrectomy and radiofrequency-assisted robotic laparoscopic partial 
nephrectomy (RFRCPN).  In the robotic arm, the procedure involved the use of a novel 
radiofrequency ablation probe to achieve haemostasis without clamping the renal hilum. 
There was no evidence of a difference in adverse events [10] or postoperative renal function  
(Table 2).  Mean (range) WIT in the laparoscopic partial nephrectomy group was 31 (0-52) 
minutes (Table 2).   
 
 
3.2.6 Are minimally invasive ablative procedures better than partial or radical 
nephrectomy? 
 
i. Laparoscopic-assisted cryoablation vs. partial nephrectomy  
Two studies compared laparoscopic cryoablation with laparoscopic partial nephrectomy. 
One was a prospective NRS (Desai 2005b) [39] whilst the other was a matched-pair study 
(O’Malley 2007) [40]. There was no evidence of a difference in perioperative outcomes, 
recovery times, complication rates [39,40] (Figs 2, 3 and 5) or postoperative serum 
creatinine [39,40] (Table 2). Mean (SD) WIT was 30.2 (8.5) minutes and 27.6 (6) minutes in 
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the laparoscopic partial nephrectomy arms in Desai’s and O’Malley’s studies respectively 
(Table 2). Blood loss was significantly less in the laparoscopic cryoablation group [39,40] (Fig 
6).  O’Malley [40] found that laparoscopic cryoablation was significantly quicker than 
laparoscopic partial nephrectomy but there was no evidence to suggest a difference in 
Desai’s study [39] (Fig 7).  However, these results should be interpreted cautiously as the 
indications for both procedures are likely to be different. For instance, partial nephrectomy 
is usually indicated for tumours of up to 4cm, whereas minimally invasive ablative 
procedures are usually reserved for tumours up to 3cm only, and  in  patients unfit for 
partial nephrectomy [5].  Furthermore, as the reports are NRS, it is likely that the study 
populations are heterogeneous.  
 
One other matched-comparison study compared laparoscopic cryoablation with open 
partial nephrectomy (Ko, 2008) [41].  Length of hospital stay was significantly shorter (Fig 2) 
and mean blood loss was significantly less (Fig 6) in the laparoscopic cryoablation group.  
There was no evidence of a difference in the number of patients requiring a blood 
transfusion or duration of operation (Figs 3 and 7).   
 
ii. Laparoscopic-assisted HIFU or RFA vs. radical or partial nephrectomy  
No eligible studies that compared laparoscopic-assisted HIFU or RFA against either partial or 
radical nephrectomy were identified.  
 
 
3.2.7 Does ipsilateral lymphadenectomy or ipsilateral adrenalectomy result in 
worse perioperative outcomes during partial or radical nephrectomy? 
A sub-group analysis of a large RCT was performed after obtaining the trial data (EORTC 
30881; Blom 2009) [42].  The groups were comparable in terms of postoperative 
complications, although event rates were generally low. The commonest complications 
included bleeding (6.7% vs. 4.6%), embolism (2% vs. 0.4%) and infection (5.1% vs. 5.8%) for 
complete lymph node dissection vs. no dissection respectively. The differences were not 
significant (Table 2); however, the subgroup analysis was underpowered because the trial 
was not designed to test this hypothesis. 
 
There were no comparative studies that assessed perioperative or QoL outcomes for 
ipsilateral adrenalectomy at the time of partial or radical nephrectomy. 
 
 
4 Discussion 
 
4.1 Principal Findings: 
 
The objective of this review was to determine the comparative perioperative and QoL 
outcomes of all surgical and minimally-invasive interventions used in the treatment of 
localised renal cancer. It is important to emphasise that treatment decisions are usually 
made on the basis of oncological outcomes. However, in instances where oncological 
outcomes are equivalent between interventions, then the emphasis shifts onto other 
outcomes, including perioperative and QoL outcomes. In addition, where there is 
uncertainty regarding oncological outcomes, any differences in perioperative outcomes 
 13 
should be interpreted accordingly. It is therefore important the findings from this review be 
considered in conjunction with the findings of our companion study [9]. 
 
For the comparison of techniques or approaches in performing radical nephrectomy, it can 
be concluded that laparoscopic radical nephrectomy is associated with shorter hospital stay, 
shorter convalescence time and lesser analgesic requirement compared with open radical 
nephrectomy. Given that laparoscopic and open radical nephrectomy appear to offer 
equivalent survival for localised renal cancers [9], if radical nephrectomy was indicated, it 
would seem prudent for the procedure to be performed laparoscopically. There was no 
evidence that alternative approaches, such as the retroperitoneal approach, or techniques, 
such as the hand-assisted, robot-assisted, or single port techniques, are better than the 
standard 3-port, transperitoneal approach. In practice, the choice of approach is also 
influenced by tumour location, patient’s body habitus, previous intra-abdominal surgery and 
surgeon factors such as personal preference, technical skill and learning curve.     
For the comparison of partial nephrectomy versus radical nephrectomy, the review found 
that partial nephrectomy results in better preservation of renal function and other QoL 
outcomes. This advantage is maintained regardless of choice of technique or approach of 
partial nephrectomy and this is consistent with data from other studies [43-46]. 
Consequently, we conclude that for tumours in which oncological outcomes have been 
shown to be equivalent amongst interventions, partial nephrectomy should be the 
preferred approach. Nevertheless, there is still a limited understanding of how the 
advantage in terms of preservation of renal function translates to long term morbidity or 
disease-specific mortality, including cardiovascular-related mortality [47].  In terms of how 
partial nephrectomy should be performed, it remains unclear if a laparoscopic approach 
offers better perioperative or QoL outcomes than an open approach. Lastly, in considering 
the potential benefits of nephron-sparing surgery in terms of preserving renal function, an 
important factor to bear in mind is ischaemia time, which should be minimised. However, 
notwithstanding the study limitations, in this review we found that WIT of approximately 30 
minutes did not appear to compromise renal function in comparison with shorter WIT.    
 
With regard to how minimally invasive ablative procedures compare with either partial or 
radical nephrectomy, data was available for laparoscopic-assisted cryoablation only. The 
studies  reported different non-oncological outcomes such as blood loss and recovery time, 
but uniformly had high risks of bias, making definitive conclusions problematic. The absence 
of comparative studies for other laparoscopic-assisted ablative procedures such as RFA and 
HIFU was noteworthy. Consequently, until more robust and high quality comparative data 
become available, no minimally invasive ablative procedures can be considered superior to 
nephrectomy for perioperative or QoL outcomes. As such, evidence-based decision making 
for utilizing these techniques should be made based on oncological outcomes.  It is 
important to note that presently there is considerable uncertainty with regard to the impact 
of these minimally invasive ablative procedures on oncological outcomes [9,48], and these 
interventions should not be considered oncologically superior nor equivalent to either 
radical or partial nephrectomy. Therefore, it would be difficult to justify such novel 
treatment except for patients in whom surgery is inappropriate.   
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This review found no statistically significant differences in the rate of surgical complications 
between lymphadenectomy versus no lymphadenectomy when performing radical 
nephrectomy. However, this finding was based on a single study which was not adequately  
powered to address this issue. There was no comparative study on which to make 
conclusions concerning concomitant adrenalectomy during radical or partial nephrectomy in 
relation to perioperative or QoL outcomes. Although the decision to undertake 
lymphadenectomy or ipsilateral adrenalectomy should be oncologically driven, comparative 
data on perioperative, QoL and adverse effect outcomes for these procedures are important 
because such data can be used to counsel patients appropriately and to facilitate service 
provision.   
 
 
This review highlights several important gaps in knowledge in the evidence base. Only 7 of 
the 29 included studies were RCTs, which reflects the generally low quality of available 
evidence. Very few studies assessed QoL outcome measures. Patients with RCC are 
increasingly presenting at an earlier stage of their disease; indeed data from prospective 
studies show that the majority of tumours diagnosed are localised and <7cm. Such small 
RCCs are generally associated with a good prognosis, such that the focus is now shifting to 
procedures that are not only minimally invasive but also focal in nature in order to preserve 
renal function. Central to the comparative assessment of such procedures is their impact on 
generic and disease-specific QoL measures. It is imperative that future studies of novel 
therapies on localised renal cancer include QoL outcomes. Outcomes such as operative 
complications or QoL data were extremely heterogeneous between studies such that it 
became impossible to compare or pool data for meta-analysis in this review.  The lack of 
standardisation in outcome reporting is reflected also in the GRADE evidence profiles [10]. 
In addition, the review also reflected the generally poor quality of surgical research 
concerning the management of localised renal cancers. There needs to be a systematic and 
methodical approach towards studying complex surgical procedures, and initiatives such as 
IDEAL [49] provide a structured and accountable process by which surgical interventions are 
evaluated properly in prospective developmental studies, randomized trials and prospective 
databases and registries.  
 
An updated literature search performed in January 2012 (covering the period of October 
2010 to January 2012) returned 240 abstracts, of which 13 studies were relevant to our 
review. Of these, two were RCTs [50,51] and one was a prospective matched pair NRS [52]. 
Baik et al [50] compared laparoendoscopic single-site radical nephrectomy with 
conventional laparoscopic radical nephrectomy in an economic evaluation and found the 
two interventions comparable.  Park et al [51] also compared laparoendoscopic single-site 
radical nephrectomy with conventional laparoscopic radical nephrectomy and reported 
surgical and QoL outcomes.  They found that laparoendoscopic single-site radical 
nephrectomy has equivalent surgical outcomes but better QoL outcomes than laparoscopic 
radical nephrectomy.  Kiriluk et al [52] compared laparoscopic RFA or cryoablation with 
laparoscopic partial nephrectomy and found that laparoscopic partial nephrectomy had 
higher blood loss and longer operative time than laparoscopic RFA and cryoablation, but 
transfusion rate, length of hospital stay and long- term renal function outcomes were 
similar.  Of the other 10 studies identified from the updated scoping literature search, two 
were population-based registries or databases [53,54] and eight were retrospective cohort 
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studies [47,55-61]. The findings of these studies are briefly summarised in Table 3. These 
studies and other potentially relevant studies will be formally included in the next 
systematic review report update.  
 
 
4.2 Strengths and limitations of the review and discussion of how review 
findings compare with other recent systematic reviews and technology 
assessments by guideline panels 
 
The major limitations of this systematic review on surgical outcomes have been outlined in 
detail elsewhere [10].  Briefly, the strength of this report is the systematic review 
methodology and comprehensive scope. Weaknesses include the methodological 
concessions and risks of bias therein, that needed to be made to provide the best available 
evidence.  For instance, although meta-analyses are not a necessary or sufficient 
characteristic in systematic reviews, they often help in reducing uncertainty.  However, 
meta-analysis was only possible in one comparison, due to data heterogeneity. 
 
The discussion of this review in relation to the EAU and AUA guidelines, and other published 
systemic reviews is also covered comprehensively elsewhere [9,10].  Briefly, the main 
difference lies in the strict inclusion criteria and assessment of the quality of evidence.  
 
 
5.  Conclusions 
 
In terms of perioperative and QoL outcomes, partial nephrectomy results in significantly 
better preservation of renal function over radical nephrectomy regardless of choice of 
approach or technique. For tumours where partial nephrectomy is not technically feasible 
(e.g. >4cm), there is no evidence that alternative procedures or techniques are better than 
laparoscopic radical nephrectomy which is the standard of care for these localised tumours. 
For laparoscopic radical nephrectomy, the choice of approach (e.g. transperitoneal or 
retroperitoneal) does not appear to impact on outcome. With regard to technical 
modifications of laparoscopic nephrectomy, such as hand-assisted, robotic assisted or 
single-port techniques, all of them appear to have similar perioperative outcomes to 
standard laparoscopic radical nephrectomy. There is no good evidence to suggest that 
minimally invasive procedures such as cryotherapy or RFA have superior perioperative or 
QoL outcomes to nephrectomy; as such, decisions regarding such interventions should be 
based on oncological outcomes. Whilst the indication for adrenalectomy or 
lymphadenectomy is oncologically driven, its impact on perioperative and QoL outcomes 
remains unclear. Overall, there was a paucity of data regarding QoL outcomes, and when 
reported, both QoL and perioperative outcomes were inconsistently defined, measured or 
reported.  These findings should be interpreted in conjunction with the oncological 
outcomes article [9]. The current evidence base has considerable limitations due to studies 
of low methodological quality marked by high risks of bias, and hence it is imperative that 
future studies address these knowledge gaps in a prospective, robust and methodical 
manner. 
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Take Home Message 
 
Localised renal cancers are best managed by nephron sparing surgery where technically 
feasible. However, the evidence base for perioperative and quality of life outcomes has 
significant limitations due to studies of low methodological quality marked by high risks of 
bias. 
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Table 1: Baseline characteristics and perioperative and quality of life confounder adjustment 
scores 
Study/ 
confounder 
score 
 
Comparison  
N 
 
FU 
(months) 
mean (SD), 
*median 
[range] 
Age: 
Mean 
(SD), 
*median 
[range] 
Sex Male Ethnicity  N or Mean (SD) 
*median 
[range]Performance 
score (ASA unless 
otherwise stated) 
Comorbidity 
Peng 2006 
[15]; RCT 
LRN 27 [6-12] 50.67 
(15.46) 
M 15 
F 12 
NR NR  NR  
ORN 26 [6-12] 52.53 
(15.12) 
M 15 
F 11 
NR  NR  NR 
Hemal 2007 
[17]; 
prospective 
cohort 
LRN 41 51.4 [3, 78] 52.5 
(11.3) 
M 24 
F 17 
NR 1.95 (0.95)  NR 
ORN 71 57.2 [4, 80] 52.7 
(11.8) 
M 47 
F 24 
NR 1.75 (0.745)  NR 
Adjustment  ORN NA NA 1 NA 5 1 5 
Gratzke 2009 
[16];  database 
review 
(Ludwig-
Maximillian 
and Basel 
University) 
LRN 36 22 [11-71] 67.8 
(12.8) 
M 23  
F 13 
NR 1: 0 
2: 20 (56%) 
3: 16 (44%) 
4: 0 
NR 
ORN 37 22 [11-71] 61.1 
(12.7) 
 
M 23  
F 14 
NR 1:3 (8%) 
2:21 (57%) 
3:13 (35%) 
4: 0 
NR 
Adjustment  NA NA NA 5 NA 5 1 5 
Nambirajan  
2004 [19]; RCT 
RLRN 20 15 [6-26] 66.8 [43-
82] 
M 9,  
F 11  
NR 2.35  NR 
TLRN 20 17 [6-16] 62.2 [41-
80] 
M 12,  
F 8  
NR 2.05 NR 
Nadler 2006 
[20]; QRCT  
RLRN 11 *20 [0-51] 61 [42-85]  NR NR 2.2 (0.4)  NR 
TLRN 11  63 [50-86]  NR NR 2.5 [0.5] NR 
Desai 2005a 
[18]; RCT 
RLRN 52 13.5 (11.9) 
[0.5 – 40] 
64.5 
(12.3) 
[29-89] 
M 33  
F 19 
NR 2.8 (0.6) [1-4]  NR 
TLRN 50 15 (6.2) [3-
24] 
62.8 
(13.3)[30-
38] 
M 26  NR 2.7 (0.6) [2-4] NR 
Nadler 2006 
[20]; QRCT  
HALRN 11 * 20 [0-51] 61 [42-85]  NR NR 2.2 (0.4)  NR 
TLRN 11  57 [42-58]  NR NR 2.1. (0.8)  NR 
Gabr 2009b 
[21]; database 
review 
(University of 
Michigan 
Health 
System) 
HALRN 108 Overall 
35.2 (25) 
[0.3-114]; 
*30  
61.3 (12.7 M 73 
F 35 
NR ≥3: 49  NR 
TLRN 147  62.7 
(12.9) 
M 81 
F 56 
NR ≥3: 52 
P = 0.12 
 NR 
Adjustment  NA NA NA 1 NA 5 1 5 
Nadler 2006 
[20]; QRCT  
HALRN 11 * 20 [0-51] 61 [42-85] NR NR 2.2 (0.4) NR  
RLRN 11  63 [50-86] NR NR 2.5 [0.5] NR 
Hemal 2009 
[22]; 
prospective 
cohort  
Robot-RN 15 8.3 [1-12] 50.3 
(10.2) 
M 8 
F 7 
NR  NR NR 
LRN 15 9.1 [2-12] 52.7 
(11.8) 
M 6  
F9 
NR  NR NR 
Adjustment   NA NA 1 NA 5 5 5 
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Study/ 
confounder 
score 
 
Comparison  
N 
 
FU 
(months) 
mean (SD), 
*median 
[range] 
Age: 
Mean 
(SD), 
*median 
[range] 
Sex Male Ethnicity  N or Mean (SD) 
*median 
[range]Performance 
score (ASA unless 
otherwise stated) 
Comorbidity 
Soga 2008 
[24]; 
prospective 
cohort 
PLESS-RN 14 * 7.1 [2.7-
17.3]  
57 (13.5) M 8 
F 6 
NR All WHO <2  NR 
LRN 15 * 27.2 
[19.5;39.1]  
53.7 (15) M 11 
F 4 
NR All WHO <2  NR 
Adjustment  NA NA NA 1 NA 5 1 5 
Park 2009a 
[23], matched-
pair 
 
Lap single-
site (LESS) 
RN  
9 NR Matched, 
but no 
data given 
Matched, 
but no 
data 
given 
NR NR NR  
Lap RN  18 NR   NR NR  NR 
Adjustment NA NA NA 1 1 5 5 5 
Blom 2009 
[42]; RCT , 
subgroup 
analysis (note 
that baseline 
characteristics 
are considered 
randomised as 
the 
randomisation 
process 
protects 
against 
indication 
biases present 
in 
observational 
studies) 
RN+LND  271 
(sub-
group)  
*151 (max  
264) 
overall 
58.7 
(10.8) 
[28-84] 
140 
(54.9% 
NR WHO 0: 216 (84.7%) 
WHO 1: 31 (12.2%) 
WHO 2: 7 (2.7%) 
WHO 3: 1 (0.4%) 
NR 
 RN 288 (sub-
group) 
 58.6 
(11.6)[24-
81] 
172 
(64.7%) 
NR WHO 0: 232 (87.2%) 
WHO 1: 31 (11.7%) 
WHO 2: 3 (1.1%) 
WHO 3: 0 
NR 
D’Armiento 
1997 [25]; RCT 
OPN 19 70 (max 
98) 
51.4 
(13.7) 
[23-74] 
M 14  
F 5 
NR  NR  NR 
ORN 21 70 (max 
97) 
48.7 
(14.7) 
[27-76] 
M 13 
F 8  
NR  NR  NR 
Van Poppel 
2007 [26]; RCT 
OPN 268 NR </= 60: 
117 
(43.7%),  
61-70: 93 
(34.7%)s  
>70: 58 
(21.6%) 
M 178 
F 87  
 missing 
3  
NR NR NR 
ORN 273 NR </= 
60:123 
(45.1%),  
61-70: 95 
(34.8%) 
 >70: 55 
(20.1%) 
M 178  
F 91  
missing 4 
NR NR NR 
Butler 1995 
[28]; database 
review 
(Cleveland 
Clinic) 
OPN 46 40 (26) 60 (14) M 32  
F 14  
NR  NR DM: 8 
(17%),  
HT: 29 
(63%),  
Smoke: 24 
(52%),  
Other: 8 
(17%)  
ORN 42 66 (30) 64 (13) M 22  
F 22  
NR  NR DM: 6 
(14%),  
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Study/ 
confounder 
score 
 
Comparison  
N 
 
FU 
(months) 
mean (SD), 
*median 
[range] 
Age: 
Mean 
(SD), 
*median 
[range] 
Sex Male Ethnicity  N or Mean (SD) 
*median 
[range]Performance 
score (ASA unless 
otherwise stated) 
Comorbidity 
HT: 20 
(48%),  
Smoke: 13 
(31%),  
Other: 6 
(14%)  
Adjustment  NA NA NA 1 NA 5 5 1 
Gratzke 2009 
[16]; database 
review 
(Ludwig-
Maximillian 
and Basel 
University 
OPN 44 22 [ 11-71] 60.7 
(12.4) 
M 29 
F 15 
NR 1: 2 (4%) 
2: 30 (67%) 
3: 12 (26%) 
4: 1 (2%) 
NR 
ORN 37 22 [11-71] 61.1 
(12.7) 
 
M 23  
F 14 
NR 1: 3 (8%) 
2: 21 (57%) 
3: 13 (35%) 
4: 0 
NR 
Adjustment  NA NA NA 1 NA 5 1 5 
Lee 2007 [29]; 
matched pair 
 
 
OPN 56 37.1 (26.1) 51.8 
(11.7) 
M 48 
F 8 
NA NA HT: 14   
DM: 13 
ORN 56 39 (20.37) 52.5 
(11.0) 
M 42  
F 14 
NA NA HT: 21   
DM: 11 
Adjustment   NA NA NA NA NA NA NA 
Poulakis 2003 
[27]; 
prospective 
cohort 
 
OPN 29 (sub-
group) 
*20 [14-
27] overall 
No 
baseline 
data for 
subgroups 
NR NR NR NR 
ORN 22 (sub-
group) 
 No 
baseline 
data for 
subgroups 
NR NR NR NR 
Adjustment  NA NA NA 5 NA 5 5 5 
Shekkariz 2002 
[30]; matched 
pair 
 
OPN 60  NR 62 [40-76] NR NR NR  NR 
ORN 60  NR 65 [46-81] NR NR NR NR  
Adjustment   NA NA 1 NA 5 5 5 
Simmons 2009 
[31]; database 
review 
LPN 35 * 44 (27-
85) 
63.5 (12) M 26  
F 9 
 2.7 (0.5) NR 
LRN 75 *57 (27-79) 63.4 (12) M 39 
F 36 
 2.6 (0.6) NR 
Adjustment NA NA NA 1 NA 5 1 5 
Dash 2006 
[32]; database 
review (Sloan-
Kettering) 
O/LPN 45 *21  56.7 (13) M 32  
F13 
NR NR  Vascular 
invasion 
absent: 19  
Present: 1 
Unknown: 
25  
ORN 151 *21 63.1 
(11.5) 
M 99 
F 52 
NR NR Vascular 
invasion 
absent: 97 
Present: 6 
Unknown: 
48 
Adjustment NA NA NA 1 NA 5 5 5 
Gill 2007 [33]; 
database 
review 
(Cleveland 
Clinic, Mayo 
Clinic and John 
Hopkins 
university) 
LPN 771 *14.4 [0, 
84] 
59.4 [19-
87] 
M 442   
F 329 
NR ≥3: 336/732 (45.9%) 
 
ECOG ≥1: 11/771 
(1.4%) 
Smoking 
history: 127 
 
N of solitary 
kidney: 32 
OPN 1029 *33.6 [0, 
91.2] 
61.6 
[25.7-
94.0] 
M 724 
F 305 
NR ≥3: 398/525 (75.8%) 
 
ECOG ≥1:133/903 
Smoking 
history: 417 
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Study/ 
confounder 
score 
 
Comparison  
N 
 
FU 
(months) 
mean (SD), 
*median 
[range] 
Age: 
Mean 
(SD), 
*median 
[range] 
Sex Male Ethnicity  N or Mean (SD) 
*median 
[range]Performance 
score (ASA unless 
otherwise stated) 
Comorbidity 
(14.7%) N of solitary 
kidney: 222 
Adjustment  NA NA NA 1 NA 5 5 5 
Gong   2008 
[35]; matched 
pair 
LPN 76 21.7 (25.6) 60.1 
(12.5) 
M 35   
F 41 
NR  NR NR  
OPN 77 20.6 (23.1) 57.7 
(13.6) 
M 42  
F 35 
NR NR NR 
Adjustment  NA NA NA 1 NA 5 5 5 
Lane 2010 
[34]; database 
review 
(Cleveland 
clinic) 
LPN 672 * 4 yrs [IQR 
3.3-6.8] 
* 61 [IQR 
51-69] 
M 395 
F 277 
Caucasian 
613 
(92%) 
African-
American 
33 (4.9%)  
Other 26 
(3.9) 
*2 [IQR 2-3] NR 
OPN 944 * 5.7 
[IQR3.9-
7.3] 
* 61 [IQR 
52-70] 
M 626  
F 318 
Caucasian 
825 
(87%) 
African-
American 
65 (6.8%)   
Other 54 
(5.7%) 
*2 [IQR 2-3] NR 
Adjustment  NA NA NA 1 NA 1 1 5 
Marszalek 
2009 [36]; 
matched pair 
LPN 100 44.4 (SE: 
2.4) [19.2, 
110.4]  
62.3 
[22.9-
83.4] 
M 60 
F 40 
NR NR NR 
OPN 100 42 (SE: 2.4) 
[12, 117.6]   
62.5 
[21.9-
84.6] 
M 60 
F 40 
NR NR NR 
Adjustment   NA NA 1 NA 5 5 5 
Aron 2008 
[37]; matched 
pair 
Robot-LPN 12 7.4 64 (13.8) M 8  
F 4 
NR 2 [1-3] NR 
LPN 12 8.5 61 (13.8) M 8  
F 4 
NR 2 [1-3] NR 
Adjustment   NA NA 1 NA 5 1 5 
Desai 2005b 
[39]; database 
review 
Lap-Cryo 78 (89 
tumours) 
24.6 [1-60] 65.55 
(12.69) 
[28-88] 
M 54  
F24 
NR ≥3: 55  NR 
LPN 153 (153 
tumours) 
5.8 [1-36] 60.59 
(13.19) 
[17-87] 
M 89  
F 64 
NR ≥3: 71  NR 
Adjustment  NA   1  5 5 5 
O’Malley 2007 
[40]; matched 
pair 
Lap-Cryo 15 11.9 (7.2) 76.1 (4.5) M 9   
F 6  
 ≥3: 9 >1 
comorbid: 7 
LPN 15 9.83 (8.8) 75.7 (4.6) M 12 
F 3 
 ≥3: 8 >1 
comorbid: 7 
Adjustment  NA NA NA 1 NA 5 1 1 
Ko 2008 [41]; 
matched pair 
Lap-Cryo 20 27.3 (10.8) 56.3 
(11.5) 
[24-76] 
M 14 
F 6 
NR 1: 5 
2: 7 
3: 7 
4: 1 
NR 
OPN 20 28.7 (14.9) 57.6 
(10.9) 
[44-77] 
M 15 
F 5 
NR 1: 8,  
2: 9 
3: 3 
4:  0 
NR 
Adjustment  NA NA NA 1 NA 5 5 5 
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Study/ 
confounder 
score 
 
Comparison  
N 
 
FU 
(months) 
mean (SD), 
*median 
[range] 
Age: 
Mean 
(SD), 
*median 
[range] 
Sex Male Ethnicity  N or Mean (SD) 
*median 
[range]Performance 
score (ASA unless 
otherwise stated) 
Comorbidity 
Wu 2010 [38]; 
database 
review 
(Northwestern 
University of 
Feinberg 
medical 
school) 
RFRCPN 42 25.8 [0.5, 
71.5] 
56 [27-77] M 24  
F 18 
NR ≥3: 10/41 (24.4%) NR 
LPN 36 7.8 [1.0, 
18.9] 
58 [36-79] M 22 
F 14 
NR ≥3: 11/34 (30.6%) NR 
Adjustment  NA NA NA 2 NA 5 1 5 
NA = not applicable; NR = not reported; SM = surgical management; NSM = non-surgical management; HALRN – hand-assisted 
laparoscopic radical nephrectomy; SLRN = standard laparoscopic radical nephrectomy; RLRN = retroperitoneal laparoscopic radical 
nephrectomy; TRLRN = transperitoneal laparoscopic radical nephrectomy; Robotic RN = robotic radical nephrectomy; LRN = laparoscopic 
radical nephrectomy; PLRN = portless laparoscopic radical nephrectomy; RN = radical nephrectomy; RN+LND = radical nephrectomy + 
lymph node dissection; OPN = open partial nephrectomy;  ORN = Open radical nephrectomy; LPN = laparoscopic partial nephrectomy;  
O/LPN = open or laparoscopic partial nephrectomy; O/LRN = open or partial laparoscopic radical nephrectomy;  RF-RCPN = radiofrequency 
assisted robotic clampless partial nephrectomy; Lap-cryo = laparoscopic cryoablation; DM = Diabetes Mellitus; HT = Hypertension; Smoke 
= smoker  
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Table 2: Renal function, postoperative complications and quality of life outcomes 
Experimental 
(Exp) 
Control (Ctr) Author Outcome N at 
baseline 
Value Reported P values Note 
Exp Ctr Exp Ctr 
Laparoscopic 
radical 
nephrectomy  
  
Open radical 
nephrectomy  
  
Gratzke 
2009 [16] 
Post op renal 
function  
36 37 34% 18% NR Measure by  % change in serum 
creatinine 6 months after 
baseline   
Gratzke 
2009 [16] 
QoL – SF 36 mental  
component  
36 37 48 48.3 p-values (between 
the three treatment 
groups) were not 
significant and were 
within 1 SD of the 
age matched norm 
At mean Fu of 22 months 
Gratzke 
2009 [16] 
QoL – SF 36 physical  
component  
36 37 47.4  48 p-values (between 
the three treatment 
groups) were not 
significant and were 
within 1 SD of the 
age matched norm 
At mean Fu of 22 months 
Radical 
nephrectomy with 
limited or 
extended lymph 
node dissection  
Radical 
nephrectomy  
Blom 2009 
[42] 
Postoperative 
bleeding  >1L 
271 288 6.7%   4.6% n.s  
Blom 2009 
[42] 
Embolism 271 288 2% 0.4% n.s  
Blom 2009 
[42] 
Postoperative 
infection  
271 288 5.1% 5.8% n.s  
Open partial 
nephrectomy  
 
Open radical 
nephrectomy  
 
Gratzke 
2009  [16] 
Mean [range] 
minutes WIT 
36  37 18 [9, 39] NA NA  
Gratzke 
2009 [16] 
QoL – SF 36 mental  
component  
34 27 44.5   48.3 p-values (between 
the three treatment 
groups) were not 
significant and were 
within 1 SD of the 
age matched norm 
 
Gratzke 
2009 [16] 
QoL – SF 36 physical  
component  
34 27 47.2   48 p-values (between 
the three treatment 
groups) were not 
significant and were 
within 1 SD of the 
age matched norm 
 
Van 
Poppel 
2007 [26] 
Postoperative renal 
function 
268 273 1.29 mg/dl 1.50 mg/dl >0.0001 Measured by median Creatinine 
level 
Butler  Postoperative renal 46 43 preoperative: 1.3 (0.4) preoperative: 1.1 (0.3)  Measured as difference between 
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Experimental 
(Exp) 
Control (Ctr) Author Outcome N at 
baseline 
Value Reported P values Note 
1995 [28] function mg/dL vs. postoperative: 
1.3 (0.6)  mg/dL,  
preoperative: 115 (35) 
µmol/L vs. postoperative: 
115 (53) µmol/L (p = n.s) 
mg/dL vs. postoperative: 
1.5 (0.4)  mg/dL,  
Preoperative: 97 (26) 
µmol/L vs. postoperative: 
133 (35) µmol/L (p = 
<0.001). 
preoperative and postoperative 
mean (SD) serum creatinine level  
 
 
  Lee 2007 
[29] 
Renal function – 
narrative 
description (data 
not shown) 
56 56    A significantly greater proportion 
of patients in the radical 
nephrectomy group had impaired 
postoperative renal function 
(defined as serum creatinine > 
1.6mg/dL) after controlling for 
diabetes, hypertension and age  
Laparoscopic 
partial 
nephrectomy  
Laparoscopic 
radical 
nephrectomy   
Simmons 
2009 [31] 
Estimated GFR 
decrease  
35 75 13 ml/min 24 ml/min 0.03  
Simmons 
2009 [31] 
2 stage CKD 
increase  
35 75 0% 12% <0.001  
Simmons 
2009 [31] 
Mean (SD) minutes 
WIT 
35 75 37 (11) NA NA  
Open or 
laparoscopic 
partial 
nephrectomy  
Open or 
Laparoscopic 
radical 
nephrectomy   
Dash 2006 
[32] 
Mean postoperative 
creatinine  
45 151    Mean difference at 3 months: 
0.23 mg/dl; 95% CI 0.11-0.34, p < 
0.0001 
Dash 2006 
[32] 
Mean postoperative 
creatinine  
45 151    Mean difference at 6-12 months: 
0.21 mg/dl, 95% CI 0.09-0.34, p < 
0.0001 
Laparoscopic 
partial 
nephrectomy 
Open partial 
nephrectomy  
Marszalek 
2009 [36] 
Decline in GFR 
(immediate)  
100 100 8.8% 0.8% <0.001  
Marszalek 
2009 [36] 
Decline in GFR (at 
3.6 years mean FU) 
100 100 10.9% 10.6% 0.8  
Gong 2008 
[35] 
Postoperative 
change in creatinine  
76 77 0.03 mg/dL 0.21 mg/dL 0.27  
Gill 2007 
[33] 
Lowest SCr in 90 
days  
771 1029 1.18 mg/dL 1.42 mg/dL n.s.  
  Marszalek 
2009 [36] 
Median [IQR] 
minutes ischaemia 
time  
100 100 23 [19, 27] (WIT) 31 [24, 45] (CIT) <0.001  
  Gong 2008 
[35] 
Mean (SD)  minutes 
ischaemia time 
76 77 32.8 [10.6] (WIT) 20.5 [6.5] (all CIT, apart 
from 1 patient) 
<0.001  
  Gill 2007 
[33] 
Mean [range] 
minutes WIT 
648 461 30.7 [4, 68] 20.1 [4, 52]  Multivariate adjusted relative risk 
(95% CI), LPN vs. OPN: 1.69 (1.62, 
1.77) p = < 0.0001 
Robotic partial 
nephrectomy 
Laparoscopic 
partial 
Aron 2008 
[37] 
Mean GFR at 3 
month post 
12 12 75 mg/dL 72 mg/dL 0.71  
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Experimental 
(Exp) 
Control (Ctr) Author Outcome N at 
baseline 
Value Reported P values Note 
nephrectomy operation  
Aron 2008 
[37] 
Mean (SD) minutes 
WIT 
12 12 23 (6.6) 22 (10.8) 0.89  
Aron 2008 
[37] 
Mean (SD) minutes 
WIT in 6 patients  in 
each arm who had 
early unclamping 
6 6 21 (6.5) 14 (3.5) 0.05  
Laparoscopic 
cryoablation  
Laparoscopic 
partial 
nephrectomy 
Desai 
2005b [39] 
Mean rise in Serum 
creatinine from 
baseline  
78 153 16.4 (21)%  13.7 (37.9)  % 0.081 % Rise in serum creatinine = 
Serum creatinine at 1 month 
minus Baseline serum creatinine 
divided by Baseline serum 
creatinine multiplied by 100. 
O’Malley 
2007 [40] 
Mean postoperative 
creatinine 
15 15 1.18 (0.24) mg/dL 1.19 (0.29) mg/dL 0.89  
Desai 
2005b [39] 
Mean (SD) minutes 
WIT 
78 153 NA 30.2 (8.5) NA  
O’Malley 
2007 [40] 
Mean (SD) minutes 
WIT 
15 15 NA 27.6 (6) NA  
RFRCPN Laparoscopic 
partial 
nephrectomy 
Wu 2010 
[38] 
Mean change in 
serum creatinine 
from baseline to last 
axial radiological 
imaging  
41 36 0.16 mg/dL 0.13 mg/dL 0.58  
Wu 2010 
[38] 
Mean [range] 
minutes WIT 
42 36 NA 31.1 [0, 52] NA  
WIT = warm ischaemia time; CIT = cold ischaemia time; LPN = laparoscopic partial nephrectomy; OPN = open partial nephrectomy; NA = not applicable; n.s = not significant   
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Table 3: Brief summary of findings from studies identified in an updated scoping search (October 2010-January 2012) 
Study  Study design  Experimental Control  Brief summary of findings 
Sun 2012 [47] Retrospective cohort OPN LPN    Perioperative outcomes only: LPN has fewer adverse outcomes than OPN. 
Altunrende 
2011 [55] 
Retrospective cohort (in 
patients with a solitary kidney) 
Cryotherapy RFA Oncological and functional outcomes: No evidence of a difference 
Baik 2011 [50] RCT LESS LRN   Economic evaluation: LESS comparable with LRN in economic terms. 
Bouliere 2011 
[56] 
Retrospective cohort (tumours 
<4cm only) 
PN RN Renal function outcome only: PN better than RN. 
Jeon 2011 
[57] 
Retrospective cohort 
(Tumours >7cm only) 
LRN ORN Oncological and surgical outcomes: No evidence of a difference but LRN less invasive than ORN. 
Kates 2011 
[53] 
Population-based 
registry(tumours <2cm only) 
PN RN Overall and cardiovascular mortality: PN better for both outcomes. 
Kiriluk 2011 
[52] 
Prospective matched-control 
study 
LRFA LPN Perioperative and renal functional outcomes: LPN had higher blood loss and longer operative time; but transfusion rate, length of 
hospital stay and long term renal function outcome similar.  
Mir 2011 [58] Retrospective cohort LESS LRN   Perioperative outcomes only: No evidence of a difference 
Mitchell 2011 
[59] 
Retrospective cohort (in 
patients with a solitary kidney) 
PA  PN Renal function outcome only: No evidence of a difference 
Park 2011 [51] 
 
 
RCT LESS LRN   Perioperative and QoL outcomes: No evidence of a difference in perioperative outcomes but LESS had better QoL outcomes than LRN. 
Takagi 2011 
[60] 
Retrospective cohort (in 
patients with chronic kidney 
disease) 
PN RN Overall survival and renal function outcome only: PN could significantly prevent development to late-stage CKD in patients with 
preoperative e-GFR 45-59 mL/min/1.73 m2 compared with RN.  However, there was no evidence of a difference between groups in 
overall survival and the number of the patients who went on to develop end-stage renal disease requiring renal replacement therapy.  
Tan 2011 [54] Population-based registry 
(SEER database) 
LRN    ORN    Perioperative outcomes only: LRN had lower ICU admission and prolonged length of stay, but higher in-hospital mortality. 
White 2011 
[61] 
Retrospective cohort Robotic LESS LRN    Perioperative outcomes only: No evidence of a difference  
OPN = Open partial nephrectomy; LPN = Laparoscopic partial nephrectomy; RFA = Radiofrequency ablation; LESS = Laparoendoscopic single-site radical nephrectomy; LRN = Laparoscopic radical nephrectomy; 
PN = Partial nephrectomy; RN = Radical nephrectomy; PA = percutaneous ablation ORN = Open radical nephrectomy; LRFA = Laparoscopic Radiofrequency ablation; LPN = Laparoscopic partial nephrectomy; 
Robotic LESS = Robotic Laparoendoscopic single-site radical nephrectomy.  
 
 31 
 
 
 
 
 
 32 
 
Figure 2: Length of hospital stay (days, mean, SD) 
Study or Subgroup
1.1.1 Laparoscopic radical (exp) vs. open radical (ctr) nephrectomy
Gratzke et al  [16]
Hemal et al [17]
Peng et al [15] (RCT)
1.1.2 Retroperitoneal (exp) vs. transperitoneal (ctr) laparascopic radical nephrectomy
Desai et al [18] (RCT)
Nadler et al [20] (Q-RCT)
Nambirajan et al[19](RCT)
1.1.3 Hand-assisted (exp) vs. transperitoneal (ctr) laparospic radical nephrectomy
Nadler et al [20] (Q-RCT)
1.1.4 Hand-assisted (exp) vs. retroperitoneal (ctr) laparoscopic radical nephrectomy
Nadler et al [20] (Q-RCT)
1.1.5 Hand-assisted (exp) vs. trans- or retro-peritoneal (ctr) laparoscopic radical nephrectomy
Gabr et al [21]
1.1.6 Robotic (exp) vs. laparoscopic (ctr) radical nephrectomy
Hemal et al [22]
1.1.7 Portless endoscopic (exp) vs. laparoscopic (ctr) radical nephrectomy
Park et al [23]
Soga et al [24]
1.1.8 Open partial (exp) vs. open radical (ctr) nephrectomy
Buttler et al [28]
Gratzke et al  [16]
Shekarriz et al [30]
1.1.9 Laparoscopic partial (exp) vs. open partial (ctr) nephrectomy
Gill et al [33]
Gong et al  [35]
1.1.10 Robotic (exp) vs. laparoscopic (ctr) partial nephrectomy
Aron et al [37]
1.1.11 Laparoscopic cryoablation (exp) vs. laparoscopic partial nephrectomy (ctr)
Desai et al [39]
O'Malley et al [40]
1.1.12 Laparoscopic cryoablation (exp) vs. open partial nephrectomy (ctr)
Ko et al [41]
Mean
7.2
3.6
6.92
1.87
3.6
7.6
3.4
3.4
2.8
3.5
2.7
9.7
9.2
9.6
6.4
3.3
2.5
4.7
2.1
3.3
4.21
SD
2.9
0.79
0.96
1.28
1.9
4.7
1.7
1.7
1.6
0.1
0
4.5
6.1
3.1
3
0
2.1
2.4
2.9
3.3
1.5
Total
36
41
27
52
11
20
11
11
108
15
9
14
46
44
60
771
76
12
78
15
20
Mean
9.1
6.6
11.42
1.81
2.1
7.2
2.1
3.6
2.4
3.4
3.9
9.5
8.5
9.1
6.4
5.8
5.6
4.4
2.3
4.4
8.2
SD
3.5
1.06
1.57
1.43
0.7
2.7
0.7
1.9
1.7
0.2
0
2.3
3.4
3.5
3.3
0
3
1.1
2.8
3.9
2.4
Total
37
71
26
50
11
20
11
11
147
15
18
15
42
37
60
1029
77
12
153
15
20
IV, Fixed, 95% CI
-1.90 [-3.37, -0.43]
-3.00 [-3.35, -2.65]
-4.50 [-5.20, -3.80]
0.06 [-0.47, 0.59]
1.50 [0.30, 2.70]
0.40 [-1.98, 2.78]
1.30 [0.21, 2.39]
-0.20 [-1.71, 1.31]
0.40 [-0.01, 0.81]
0.10 [-0.01, 0.21]
Not estimable
0.20 [-2.43, 2.83]
0.70 [-1.34, 2.74]
0.50 [-0.95, 1.95]
0.00 [-1.13, 1.13]
Not estimable
-3.10 [-3.92, -2.28]
0.30 [-1.19, 1.79]
-0.20 [-0.98, 0.58]
-1.10 [-3.69, 1.49]
-3.99 [-5.23, -2.75]
Experimental Control Mean Difference Mean Difference
IV, Fixed, 95% CI
-10 -5 0 5 10
Favours experimental Favours control
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Figure 3: Blood transfusion (number of patients). 
Study or Subgroup
1.2.1 Laparoscopic radical (exp) vs. open radical (ctr) nephrectomy
Gratzke et al  [16]
Hemal et al [17]
1.2.2 Retroperitoneal (exp) vs. transperitoneal (ctr) laparascopic radical nephrectomy
Nambirajan et al[19](RCT)
1.2.3 Hand-assisted (exp) vs. trans- or retro-peritoneal (ctr) laparoscopic radical nephrectomy
Gabr et al [21]
1.2.4 Robotic (exp) vs. laparoscopic (ctr) radical nephrectomy
Hemal et al [22]
1.2.5 Portless endoscopic (exp) vs. laparoscopic (ctr) radical nephrectomy
Soga et al [24]
1.2.6 Open partial (exp) vs. open radical (ctr) nephrectomy
Buttler et al [28]
Gratzke et al  [16]
Shekarriz et al [30]
1.2.7 Laparoscopic partial (exp) vs. open partial (ctr) nephrectomy
Gill et al [33]
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Figure 4: Analgesic requirement (mg morphine equivalent, mean, SD). 
Study or Subgroup
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Figure 5: Convalescence time (weeks, mean, SD) 
Study or Subgroup
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Figure 6: Blood loss (ml, mean, SD). 
Study or Subgroup
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Figure 7: Duration of operation (minute, mean, SD). 
Study or Subgroup
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Figure 8: Return to work at 2 weeks (number of patients). 
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Figure 9: Time to nonstrenuous activity (days, mean, SD). 
Study or Subgroup
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Appendix 1.  Assessment of risk of bias*  
Study ID Randomised? Adequate 
sequence 
generation? 
Allocation 
concealment? 
Blinding for 
Surgical 
outcomes   
Blinding for 
QoL 
outcomes 
Incomplete 
outcome 
addressed for 
surgical 
outcomes?   
Incomplete 
outcome 
addressed for 
QoL 
outcomes? 
Free of 
selective 
outcome 
reporting? 
Free of 
other 
bias? 
Aron  2008 [37] No No No Unclear NA Yes NA Yes Unclear 
Blom 2009 [42] Yes Yes Yes Unclear NA Yes NA Yes No  
Butler  1995 [28] No No No Unclear NA Yes NA Unclear Unclear 
D’Armiento 1997 [25] Yes Yes Unclear NA NA NA NA Yes Unclear 
Dash 2006 [32] No No No NA NA NA NA Unclear Unclear 
Desai 2005a [18] Yes Yes Yes No NA Yes NA Yes Unclear 
Desai 2005b [39] No No No none  NA Unclear NA Unclear No 
Gabr 2009 [21] No No No Unclear NA Unclear NA Unclear Unclear 
Gill 2007 [33] No No No No  NA No NA Unclear Unclear 
Gong  2008 [35] No No No No  NA No NA Unclear Unclear 
Gratzke 2009 [16] No No No No No Yes No Yes Unclear 
Hemal  2007 [17] No No No Unclear NA Yes NA Unclear Unclear 
Hemal  2009 [22] No No No Unclear NA Yes NA Yes Unclear 
Ko 2008 [41] No No No No NA Yes NA Unclear Unclear 
Lane 2010 [34] No No No NA NA NA NA No Unclear 
Lee  2007 [29] No No No NA NA NA NA Unclear Unclear 
Marszalek  2009 [36] No No No No NA Yes NA Yes Yes 
Nadler  (3 arm) 2006 
[20] 
Yes No (quasi-
RCT) 
No No NA Yes NA Yes Unclear 
Nambirajan  2004 [19] Yes Unclear Unclear Unclear NA Yes NA Unclear Unclear 
O’Malley  2007 [40] No No  No Unclear NA Yes NA Yes Unclear 
Park 2009 [23] No No No Unclear NA Yes NA Unclear Unclear 
Peng  2006 [15] Yes Unclear  Unclear Unclear  Unclear   Unclear Unclear   Unclear  Unclear 
Poulakis  2003 [27] No No No NA NA NA NA Unclear Unclear 
Shekarriz  2002 [30] No No No Unclear NA Unclear NA Yes Unclear 
Simmons  2009 [31] No No No NR NA NA NA Unclear Unclear 
Soga  2008 [24] No No No Unclear NA Yes NA Unclear Unclear 
Van Poppel  2007 [26] Yes Yes Unclear Unclear NA No NA Unclear Unclear 
Wu 2010 [38] No No No Unclear NA Unclear NA Unclear Unclear 
NA = not applicable (surgical or QoL outcomes not reported) 
* According to a recommended tool for RCT by the Cochrane Handbook[11] 
 
